Retatrutide has drawn attention for promising early results in weight-loss and metabolic research. However, it is a research-grade, non-FDA-approved compound and is not intended for routine clinical use. Products marketed outside of clinical trials may carry safety, quality, and regulatory risks. Patients should understand the difference between investigational compounds and approved therapies when considering treatment options.